In a groundbreaking study that promises to reshape our understanding of prostate cancer progression and immunotherapy resistance, researchers have identified a unique subpopulation of tumor-associated macrophages (TAMs) that not only facilitate tumor growth but also enable metastasis, marking a significant leap forward in cancer biology. This discovery, led by Assistant Professor Shenglin Mei at Virginia Tech’s Fralin Biomedical Research Institute Cancer Research Center, reveals how these immune cells, traditionally viewed as defenders against disease, are covertly co-opted by tumors to foster an environment conducive to cancer survival and spread.

Macrophages, which are integral components of the innate immune system, typically serve as scavengers, engulfing pathogens and apoptotic cells while orchestrating inflammatory responses to combat infection. However, the landscape within prostate tumors presents a paradox: rather than executing their protective functions, certain macrophage subsets become reprogrammed, adopting an immune-suppressive phenotype that actively promotes tumor progression. This study uncovers the molecular identity of one such detrimental macrophage subtype, characterized by the expression of the proteins SPP1 and TREM2, which congregates within tumor cores and correlates with enhanced angiogenesis, impaired immune surveillance, and metastatic potential.

Employing cutting-edge technologies including single-cell RNA sequencing and spatial transcriptomics, the research team meticulously mapped cellular interactions and gene expression profiles at an unprecedented resolution. These spatially resolved transcriptomic analyses unveiled a striking spatial segregation within the tumor microenvironment: macrophages exhibiting pro-inflammatory, potentially anti-tumor activities were predominantly located outside tumor boundaries, whereas the SPP1/TREM2-positive macrophages deeply infiltrated the tumor mass, intimately associated with malignant cells. This spatial distribution underscores the sophisticated tumor strategy to shield itself from immune-mediated destruction.

.adsslot_ifYdhovcPE{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_ifYdhovcPE{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_ifYdhovcPE{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

The study’s integrative approach combined advanced molecular profiling with the analysis of extensive datasets from hundreds of human prostate cancer samples, validating the universality of their findings across clinical stages and models. This multi-institutional collaboration incorporated expertise from premier institutions including Harvard Medical School, Massachusetts General Hospital, the University of Chicago, and Sweden’s Karolinska Institute, enabling a comprehensive investigation into the cellular ecology of prostate cancer metastasis, particularly within the bone microenvironment where treatment options remain limited and prognosis poor.

Of particular therapeutic interest, the researchers demonstrated through in vivo experiments that blocking SPP1 in murine models of prostate cancer markedly enhanced the efficacy of immunotherapy. While immune checkpoint inhibitors have revolutionized treatment for many cancers, their success in prostate cancer has been notably limited. In this context, inhibiting the suppressive macrophage subset via an anti-SPP1 antibody not only reinstated immune activation but also facilitated the infiltration of cytotoxic T cells—the frontline effectors in tumor eradication—ultimately decelerating tumor growth and dissemination.

This revelation provides compelling evidence that targeting tumor-supportive macrophages can transform a previously refractory tumor microenvironment into one amenable to immunotherapeutic intervention. Shenglin Mei emphasizes that “although macrophages are often our allies in fighting cancer, certain specialized subtypes craft an immune-suppressive niche that thwarts the body’s natural defenses.” By reversing this immunosuppression, the study highlights an exploitable vulnerability in prostate cancer’s armor.

Prostate cancer remains a formidable global health challenge as the second most commonly diagnosed cancer among men, with nearly 1.5 million new cases worldwide recorded in 2022. Decoding the tumor microenvironment’s complex cellular players is critical for improving clinical outcomes, especially in advanced stages where metastatic spread, particularly to bone, is the primary cause of mortality. This research significantly advances that understanding by linking a discrete macrophage population to specific pathological features such as neovascularization and immune evasion.

The team’s approach leverages high-dimensional single-cell technologies alongside NanoString’s digital spatial profiling to attain both transcriptomic depth and spatial context—a methodological synergy that unveils cellular dynamics impossible to discern through traditional bulk analyses. This analytic rigor not only confirms the pathological role of the SPP1/TREM2 macrophages but also delineates their precise localization and interactions within the tumor milieu.

Furthermore, the study builds on Mei’s prior work, which mapped immunosuppressive microenvironments in bone metastases and primary prostate tumors, further expanding the atlas of tumor-immune cell interplay. These cumulative insights pave the way for novel therapeutic strategies aimed at modulating macrophage phenotypes and dismantling the protective niches that cancers engineer for themselves.

The broader implications of this work resonate beyond prostate cancer, suggesting that a nuanced understanding of immune cell subtypes and their spatial arrangement is paramount for the rational design of next-generation cancer immunotherapies. Chris Hourigan, director of the Fralin Biomedical Research Institute Cancer Research Center, underscores this sentiment, noting that “integrating cancer genomics with computational oncology is essential not just for fundamental biological insight but for unlocking actionable treatment paradigms.”

In summary, the identification of the SPP1/TREM2-expressing tumor-associated macrophage subpopulation elucidates a critical mechanism by which prostate cancer orchestrates immune evasion and metastasis. By illuminating this intricate cellular crosstalk and providing a tangible target for therapeutic intervention, this study opens promising avenues for enhancing the effectiveness of immunotherapy in one of the most challenging cancer types. As precision medicine continues to evolve, such interdisciplinary and collaborative efforts exemplify the transformative potential of modern cancer research.

Subject of Research: Cells
Article Title: Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
News Publication Date: July 2, 2025
Web References: Molecular Cancer Research Article
References: DOI: 10.1158/1541-7786.MCR-24-0791
Image Credits: Journal cover by Molecular Cancer Research; photo by Virginia Tech
Keywords: Cancer, Prostate cancer, Metastasis, Health care

Tags: angiogenesis and cancer metastasiscancer biology advancementsimmune cells and cancer progressionimmunotherapy resistance mechanismsmacrophage reprogramming in tumorsmolecular identity of immune cellsovercoming immune suppression in tumorsprostate cancer research breakthroughsprostate cancer treatment resistancesingle-cell RNA sequencing in cancer researchspatial transcriptomics in immunologytumor-associated macrophages in cancer